AKT1 and atherosclerosis: Ginkgolide B (30 mg/kg−1/d−1) administered by gavage can reduce atherosclerosis in apolipoprotein E null (ApoE−/-) mice and inhibit platelet release by blocking the thrombin and collagen activation of the platelet PI3K/Akt pathway (Jackson et al., 2005) (Figure 2D).